Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06113003 · ClinicalTrials.gov registry record · Early Phase 1
The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease
A Early Phase 1 study of HIV and Non-alcoholic Fatty Liver Disease, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT06113003: Recruiting Early Phase 1 study of HIV and Non-alcoholic Fatty Liver Disease, sponsored by Vanderbilt University Medical Center.
NCT06113003 is a Early Phase 1 study of HIV and Non-alcoholic Fatty Liver Disease that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 63 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06113003, a Early Phase 1 study of HIV and Non-alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
Persons with human immunodeficiency virus (HIV) have higher risk of developing fatty liver disease (NAFLD) than HIV-negative persons but the reasons for this discrepancy are not known. Changes in the intestinal microbiome may contribute to the development of NAFLD in persons with HIV (PWH) through impairment of barrier function of the intestinal wall and by producing metabolites that are harmful to the liver. This project will test the hypothesis that HIV-related NAFLD is associated with differences in the intestinal microbiome and that supplementation with probiotic and prebiotic fiber will lead to improvements in markers of NAFLD in PWH.
Primary Outcome
Plasma phosphatidylcholine abundance is measured
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Probiotic
- DIETARY_SUPPLEMENT Prebiotic
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2024-04-18 |
| Est. Completion | 2026-03-01 |
| Phase | Early Phase 1 |
What NCT06113003 shows while recruiting
NCT06113003 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Probiotic is the first listed.
NCT06113003 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06113003 about?
NCT06113003 is a clinical study titled "The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease". Persons with human immunodeficiency virus (HIV) have higher risk of developing fatty liver disease (NAFLD) than HIV-negative persons but the reasons for this discrepancy are not known. Changes in the intestinal microbiome may contribute to the development of NAFLD in persons with HIV (PWH) through i...
What is the current status of trial NCT06113003?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 63 participants. The study started on 2024-04-18. Estimated completion is 2026-03-01.
What conditions does trial NCT06113003 study?
This clinical trial studies the following conditions: HIV, Non-alcoholic Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease.
What interventions are being tested in trial NCT06113003?
The interventions under investigation include: Probiotic (DIETARY_SUPPLEMENT), Prebiotic (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06113003?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06113003 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06113003's enrollment target sits among peer trials
63 197th of 303 higher than 106 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs
COMPLETED · Early Phase 1
-
Transitional Housing and HIV Health
RECRUITING
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
RECRUITING
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI